Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs ( n = 83,464 ) or SGLT-2 inhibitors ( n = 78,366 ), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs ( n = 108,322 ) or DPP-4 inhibitors ( n = 55,411 )
LEADER (liraglutide) [44], SUSTAIN-6 (semaglutide) [67], and REWIND (dulaglutide) [70] study showed beneficial renal outcomes, mainly reducing the occurrence of proteinuria
However, some of them also come with hidden fees, disappearing customer service, and questionable pharmacy partners that leave you wondering if you are making the right decision
N Engl J Med (2019) 380:34757
Although pancreatitis is not currently the focus of the MDL, new safety data from the U.K
US$ 20.27
US$ 21.65
US$ 24.32
US$ 22.09
US$ 29.47
US$ 27.97
